UK markets open in 2 hours 51 minutes

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.70-0.29 (-2.23%)
At close: 4:00PM EDT

Cara Therapeutics, Inc.

4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
United States
203 406 3700

Full-time employees80

Key executives

NameTitlePayExercisedYear born
Dr. Derek T. ChalmersCo-Founder, Pres, CEO & Director1.02MN/A1964
Mr. Thomas Charles ReillyChief Financial Officer170.59kN/A1972
Mr. Richard MakaraVP, Head of Accounting, Controller & Principal Accounting Officer420.43kN/A1971
Dr. Frédérique MenzaghiChief Scientific Officer and Sr. VP of R&D785.51kN/A1966
Mr. Scott M. TerrillionChief Compliance Officer, Gen. Counsel & Corp. Sec.587.88kN/A1963
Dr. Joana GoncalvesChief Medical Officer732.9kN/A1974
Dr. Michael E. LewisCo-Founder & Chief Scientific AdvisorN/AN/A1952
Mr. Eric VandalSr. VP of CommercialN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Corporate governance

Cara Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.